Oscar Health, Inc. (OSCR) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Oscar Health, Inc. is a healthcare technology company operating primarily in the individual and small group markets via federal and state exchanges. As of June 30, 2024, the company reported approximately 1.6 million members. Notably, the company exited the Medicare Advantage market for the 2024 plan year and announced the non-renewal of its Cigna+Oscar Small Group partnership, effective December 31, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $2,219.3 million | $1,521.5 million | $4,361.6 million | $2,991.2 million |
| Premium Revenue | $2,164.1 million | $1,475.0 million | $4,257.8 million | $2,903.6 million |
| Net Income (Loss) | $56.3 million | ($15.4 million) | $233.8 million | ($55.1 million) |
| Diluted EPS | $0.20 | ($0.07) | $0.82 | ($0.25) |
| Medical Loss Ratio (MLR) | 79.0% | 79.9% | 76.7% | 78.2% |
| SG&A Expense Ratio | 19.6% | 22.2% | 19.0% | 24.6% |
| Adjusted EBITDA | $104.1 million | $35.6 million | $323.4 million | $86.6 million |
| Cash & Equivalents | $2,268.2 million (as of June 30, 2024) | |||
| Long-Term Debt | $299.2 million (Carrying value of 2031 Notes) |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported net income of $56.3 million for Q2 2024, a significant improvement from a net loss of $15.4 million in Q2 2023. This marks the first profitable quarter in recent history.
- Revenue Growth: Total revenue increased 46% year-over-year for the quarter, driven by a 47% increase in premium revenue due to higher membership (up 63% YoY) and rate increases.
- Margin Expansion: The Medical Loss Ratio (MLR) improved to 79.0% from 79.9% in the prior year quarter, aided by favorable prior period development. The SG&A expense ratio improved to 19.6% from 22.2%, reflecting fixed cost leverage.
- Membership: Total members reached 1.58 million, up from 970,543 in Q2 2023. Growth was driven by the individual market, partially offset by the exit from Medicare Advantage and a decline in Cigna+Oscar members.
Guidance, Outlook, and Risks
- Strategic Shifts: Oscar will cease offering small group products effective December 15, 2024, following the non-renewal of the Cigna+Oscar partnership. The company will provide run-off services through 2026.
- Debt Conversion: The conditional conversion feature for the $305 million 2031 Convertible Senior Notes was satisfied in Q2 2024. Holders may convert the notes during Q3 2024. The notes have not yet been converted.
- Liquidity: The company maintains strong liquidity with $2.27 billion in cash and cash equivalents. Statutory capital and surplus for health insurance subsidiaries were $1.1 billion, exceeding minimum requirements.
- Risks: Key risks include the uncertainty of risk adjustment transfer estimates, regulatory changes (including Medicaid redeterminations), and the potential impact of the Change Healthcare cybersecurity incident on claims processing. Legal proceedings, including a securities class action regarding the IPO, remain ongoing.
Investor Verification Checklist
- Conversion Risk: Verify the potential dilution impact if holders of the 2031 Convertible Senior Notes exercise their conversion option in Q3 2024.
- Small Group Run-off: Assess the financial impact of the Cigna+Oscar partnership termination and the transition to a run-off status for small group plans.
- Risk Adjustment Accuracy: Monitor the finalization of risk adjustment transfer payments, as estimates are subject to significant variability and could materially impact future revenue.
- MLR Sustainability: Evaluate whether the improved MLR (76.7% YTD) is sustainable given the seasonal nature of medical claims and potential changes in member risk profiles.
- Legal Exposure: Review the status of the Carpenter v. Oscar Health, Inc. securities class action and other regulatory investigations for potential financial liabilities.